Newsbenzinga
X4 Pharmaceuticals Says Phase 3 Trial Of Mavorixafor In Chronic Neutropenia To Complete Enrollment In Q4; Topline Data Expected Q1 2028
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…